RESUMEN
AIM: Vascular dysfunction, oxidative stress and systemic inflammation are considered responsible for the pathophysiology of Obstructive sleep apnea syndrome (OSAS). It is thought that desaturation due to apnea-hypopnea attacks in OSAS patients activates inflammatory pathways. In this study, we aimed to reveal the relationship between inflammation parameters Systemic immune inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratios (PLR) severity of OSAS in patients who underwent polysomnography in our hospital's sleep laboratory. METHODS: We grouped our 171 patients who were followed up in our sleep laboratory with the diagnosis of OSAS according to their AHI values. We evaluated the correlation of SII, NLR, and PLR values obtained from the complete blood tests of our patients with OSAS diagnosis and OSAS severity. RESULTS: The mean NLR, PLR and SII values of patients with OSAS were statistically significantly higher than those without OSAS (p < 0.05). A positive correlation of 18% was found between the presence of OSAS and the SII value (p = 0.016). No statistically significant difference was found when comparing OSAS severity and NLR, PLR and SII values (p > 0.05). CONCLUSION: We observed that SII, NLR and PLR parameters, which are rapidly assessable systemic inflammation markers of this process, were independently associated in patients diagnosed with OSAS and that there was no change in SII, NLR, and PLR parameters with OSAS severity.
Asunto(s)
Inflamación , Polisomnografía , Índice de Severidad de la Enfermedad , Apnea Obstructiva del Sueño , Humanos , Apnea Obstructiva del Sueño/inmunología , Apnea Obstructiva del Sueño/sangre , Apnea Obstructiva del Sueño/diagnóstico , Masculino , Femenino , Persona de Mediana Edad , Adulto , Inflamación/inmunología , Inflamación/sangre , Neutrófilos/inmunología , Linfocitos/inmunología , Recuento de Linfocitos , Anciano , Estudios RetrospectivosRESUMEN
YouTube (YT) is one of the world's most well recognized video-sharing platforms that appeals to large audiences and is used by individuals to educate themselves on disease diagnosis and treatment alternatives and to distribute health-related information. Videos were searched by typing the terms "migraine botox" and "botox treatment for migraine" on the YT search bar in English. A total of 50 videos were evaluated for each term. Two independent researchers viewed the videos and documented pertinent descriptive attributes of each video, such as the upload date, number of comments, number of dislikes, number of likes, and views. The videos were analyzed and the DISCERN Global Quality Scale (GQS), Journal of the American Medical Association (JAMA) quality, and reliability scores were recorded. A total of 100 videos were assessed. The mean DISCERN score was 3.09, the mean JAMA score was 2.11, and the mean GQS score was 3.25. According to the source, 32% of the videos were uploaded by university/nonprofit physicians or professional organizations. In addition, when the DISCERN, GQS, and JAMA scores of the videos uploaded by health professionals were examined, a statistically significant difference was observed (Pâ =â .002, Pâ =â .015, and Pâ =â .002, respectively). However, no statistically significant relationship was found for the Video Popularity Index score. The reliability and quality scores of the evaluated videos uploaded by healthcare professionals for migraine Botox treatment were high, but the frequency of viewership was low. In our analysis of migraine Botox treatment videos on YT, we observed that the information on migraine Botox treatment had a wide spectrum, high-quality content, and that there were videos that may mislead viewers. In conclusion, we believe that the platform is not sufficient in its entirety, and that it should be supported with renewed, fact-checked, easy-to-understand language, and video-duration optimized videos.
Asunto(s)
Toxinas Botulínicas Tipo A , Trastornos Migrañosos , Grabación en Video , Trastornos Migrañosos/tratamiento farmacológico , Humanos , Toxinas Botulínicas Tipo A/uso terapéutico , Toxinas Botulínicas Tipo A/administración & dosificación , Reproducibilidad de los Resultados , Medios de Comunicación Sociales , Difusión de la Información/métodosRESUMEN
BACKGROUND: Tryptophan is an essential amino acid primarily metabolized by the kynurenine pathway in mammals. Intermediate metabolites emerging in this pathway have been associated with many neurogenerative diseases. This study aimed to compare tryptophan pathway metabolite levels in patients with multiple sclerosis (MS) and healthy controls and reveal the relationship of tryptophan metabolites with disease subtype and the Expanded Disability Status Scale (EDSS) score. METHODS: The study included a total of 80 MS cases [53 with relapsing remitting MS (RRMS) and 27 with secondary progressive MS (SPMS)] and 41 healthy volunteers. The patients with RRMS were further divided into relapse (RRMS-attack) and non-attack (RRMS-stable) groups. Using liquid chromatography mass spectrometry, tryptophan, kynurenine, kynurenic acid, quinolinic acid, 3-hydroxykynurenine, and 3-hydroxyanthranilic acid levels were measured. The serum metabolite levels of the patient and control groups were compared. In addition, the link and relationship between the EDSS score and disease duration of the patients and their plasma tryptophan metabolite levels were examined. RESULTS: The tryptophan level of the patient group was significantly lower than that of the healthy controls (p<0.05). The kynurenine (105.38±65.43), quinolinic acid (10.42±3.56), kynurenine/tryptophan ratio (0.0218±0.019), and quinolinic acid/kynurenic acid ratio (1.7054±0.96141) of the patients with MS were significantly higher compared to the controls (p<0.05). In the receiver operating characteristic analysis of the power of kynurenine/tryptophan and quinolinic acid/kynurenic acid ratios in predicting the disease, both ratios predicted the diagnosis of MS (area under the curve: 0.793 and 0.645, respectively; p<0.05), albeit at low sensitivity and specificity. The parameters were similar between the RRMS-attack and RRMS-stable patient groups (p>0.05). There was also no significant difference between the RRMS and SPMS patient groups in terms of tryptophan metabolites (p>0.05). Lastly, no significant relationship was observed between tryptophan metabolites and MS subtype and the EDSS score. CONCLUSION: Our findings revealed that the kynurenine pathway involved in the tryptophan metabolism differed between the patients with MS and healthy controls, and this difference may be a limited guide in the diagnosis of MS, due to major overlaps in values for MS versus Controls, and is insufficient to determine the disease subtype.
Asunto(s)
Esclerosis Múltiple , Triptófano , Animales , Humanos , Quinurenina/metabolismo , Ácido Quinurénico/metabolismo , Ácido Quinolínico , Mamíferos/metabolismoRESUMEN
Multiple sclerosis (MS) is an autoinflammatory, chronic central nervous system disease. In the pathogenesis of the disease increased nitric oxide (NO) levels play an important role. Nitric oxide (NO) has neuroprotective effects in physiological conditions, however, it is thought that excessive NO formation in MS may lead to demyelination and axonal damage. Derivatives of methylarginine including asymmetric dimethyl arginine (ADMA), L-N monomethyl arginine (L-NMMA), symmetric dimethyl arginine (SDMA) directly or indirectly reduce NO production. Our aim was to measure the levels of methylarginine derivatives and citrulline, ornithine, arginine, homoarginine levels, which are metabolites associated with NO metabolism, in MS subgroups.